ArticleHuman vaccines & immunotherapeutics2020
Hepatitis B vaccine birth dose in India: time to reconsider.
Article in Human vaccines & immunotherapeutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Immunogenicity and Safety of Biological E's Monovalent rDNA Hepatitis B Vaccine (BEVACViruses · 2026Trial
- Preventive strategies for chronic liver disease: A critical review of awareness, vaccine and screening programmes.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2026Review
- Hepatitis B infection status & vaccine coverage among under five children in Mayurbhanj district, Eastern India.The Indian journal of medical research · 2025Article
- Assessing Hepatitis B virus infection, risk factors and immunization among particularly vulnerable tribal groups in Eastern India.Scientific reports · 2025Article
- Knowledge level of healthcare professionals regarding hepatitis B immunizatıon of newborns: example of Turkey.Revista da Associacao Medica Brasileira (1992) · 2023Article
- Hepatitis B vaccination in Iran: Historical policies and programs.Journal of preventive medicine and hygiene · 2022Article
- Review
- Hepatitis B Prevalence and Risk Factors in Punjab, India: A Population-Based Serosurvey.Journal of clinical and experimental hepatologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Viral hepatitis is increasingly being recognized as a public health problem in India with 96% of all hepatitis mortality attributed to hepatitis B and C combined. It has been recognized that hepatitis B vaccination has resulted in substantial reductions in the incidence of acute and chronic hepatitis B infections and carriage. Although coverage of third-dose hepatitis B vaccine has reached 86%, the birth-dose coverage was only 45% in 2015 despite high rates of institutional deliveries (79%). With the target set at 90% coverage of birth-dose hepatitis B vaccine by 2030, it is imperative to immediately incorporate WHO/SAGE recommendations of administering the hepatitis B vaccine birth dose until 7 d into the National Immunization Schedule (NIS).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.